Connect Biopharma Holdings (CNTB) Retained Earnings (2020 - 2026)

Connect Biopharma Holdings has disclosed Retained Earnings across 7 years of filings, most recently posting $465.5 million for Q2 2026.

• In Q2 2026, Retained Earnings rose 5.46% year-over-year to $465.5 million; the TTM figure through Jun 2026 stood at $465.5 million (up 5.46% YoY), while the FY2025 annual figure was $444.2 million, up 1.1% from the prior year.
• Retained Earnings came in at $465.5 million for Q2 2026 at Connect Biopharma Holdings, roughly flat from $464.1 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $465.5 million in Q2 2026 to a low of -$531.7 million in Q2 2024.
• Average Retained Earnings over 5 years is $142.4 million, with a median of $439.8 million recorded in 2024.
• Year-over-year, Retained Earnings slipped 20.02% in 2022 and soared 196.85% in 2023.
• Over 5 years, Retained Earnings stood at -$446.4 million in 2022, then soared by 196.85% to $432.4 million in 2023, then advanced by 1.61% to $439.4 million in 2024, then grew by 1.1% to $444.2 million in 2025, then advanced by 4.8% to $465.5 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $465.5 million in Q2 2026, $464.1 million in Q1 2026, and $444.2 million in Q4 2025.